Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Peptides for Memory Loss Prevention — Comparison

Cerebrolysin Multi-peptide neurotrophic factor mimetic. Promotes synaptogenesis and reduces excitotoxicity 6 RCTs in vascular dementia (Cochrane 2019). Modest ADAS-cog improvement, high bias risk 10–30mL IV infusion, 5 days/week, 4 weeks Requires clinical admi

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Cerebrolysin
  • Multi-peptide neurotrophic factor mimetic. Promotes synaptogenesis and reduces excitotoxicity
  • 6 RCTs in vascular dementia (Cochrane 2019). Modest ADAS-cog improvement, high bias risk
  • 10–30mL IV infusion, 5 days/week, 4 weeks
  • Requires clinical administration. Not practical for self-directed prevention protocols
  • Strongest human evidence but limited to post-stroke/dementia populations, not prevention
  • Dihexa
  • HGF receptor agonist. Triggers synaptogenesis at picomolar concentrations
  • None. Preclinical rodent models only
  • Extrapolated: 1.7–17mg SC, dosing frequency unknown
  • No published human pharmacokinetics. Dosing is speculative
  • Promising mechanism but entirely untested in humans
  • P21
  • CNTF-derived BDNF modulator. Enhances memory consolidation and LTP
  • None. Rodent spatial memory studies only
  • Extrapolated: 17mg SC, 3–5x weekly
  • Bioavailability after SC injection unverified in humans
  • Mechanistically sound but lacks any human validation
  • Thymalin
  • Thymic peptide. Reduces neuroinflammation via cytokine modulation
  • Observational immune studies. No cognitive-specific RCTs
  • 5–10mg SC daily or every other day, 10–20 day cycles
  • Indirect cognitive effects through inflammation. Not a direct memory modulator
  • Plausible neuroprotective role but no direct memory loss prevention data
  • MK 677
  • Growth hormone secretagogue. Increases IGF-1 and REM sleep quality
  • Phase II trials in elderly (JCEM 1999). IGF-1 increased 72%, no cognitive endpoints measured
  • 10–25mg oral daily
  • Indirect cognitive benefit through sleep and IGF-1. Not a targeted memory compound
  • Improves factors correlated with memory (sleep, GH axis) but not proven to prevent memory loss